Summary
In 2024, the 7MM reported approximately 35,000 incident BMF cases, highlighting the persistent clinical burden and the ongoing need for earlier diagnosis and more effective treatment strategies.
ROMIPLATE has made notable regulatory progress in Japan, its only approved market for aplastic anemia, expanding from a restricted indication for refractory patients in 2019 to full approval for all aplastic anemia cases in 2023, reinforcing its increasing clinical importance within the country’s therapeutic landscape.
Teva’s 2023 FDA approval of ALVAIZ for adults with severe aplastic anemia unresponsive to immunosuppressive therapy expands treatment options...
